Skip to main content
OpenTrials
Completed

NCT Number: NCT01030094

A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy

The purpose of this study is to investigate the influence of topiramate monotherapy on the bone and mineral metabolism markers, and bone density (the amount of mineral per square centimeter of bone ) in female participants with epilepsy (seizure disorder), before menopause (time in life when a woman stops having a menstrual period), as compared with healthy participants and comparative group received either carbamazepine or valproic acid monotherapy for at least last one year.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Seizures Bone Diseases Bone Diseases, Metabolic Brain Diseases Central Nervous System Diseases Convulsions Epilepsy Metabolic Diseases Musculoskeletal Diseases Nervous System Diseases Neurologic Manifestations Nutritional and Metabolic Diseases Osteopenia Osteoporosis Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

About this study

This is a cross-sectional (observations or measurements made at a single point in time, usually at participant enrollment), multi-center (conducted in more than one center), and comparative study of topiramate monotherapy in female participants with epilepsy. Female participants must have received either topiramate, carbamazepine, or valproic acid monotherapy for more than one year for the treatment of epilepsy. Blood samples will be obtained from fasting participants to investigate the effect of study drug on the bone and mineral metabolism markers, and bone density compared to healthy participants and comparative group (carbamazepine and valproic acid monotherapy). Bone mineral density will be measured from the participants' lumbar spine or femur. A survey of food intake and physical activity for the participants will be performed using a standardized validated detailed questionnaire. The post-study visit (or follow up phone contact) will be performed for the occurrence of serious adverse events (SAE) for safety evaluation. Participants' safety will be monitored throughout the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who agree to participate in this study
  • Female epileptic participants
  • Participants who are receiving topiramate, carbamazepine or valproic acid monotherapy for more than one year
  • Participants who are using proper contraceptive method (s) or have a negative pregnancy test result

Exclusion criteria

  • Participants with a motor function disorder
  • Participants with a disease which affects their skeleton including primary hyperparathyroidism, Paget's disease, multiple myeloma, liver and kidney disorder, thyroid disease, malabsorption disorder, diabetes, and malignancies
  • Participants who have taken within last one year, or are currently taking a drug which affects the bone and mineral metabolism such as vitamin D, calcium, anabolic steroids, bisphosphonates, calcitonin, glucocorticoids, and diuretics
  • Voluntary or surgical postmenopausal participants
  • Participants with amenorrhea for more than 6 months

Treatment and study plan

Topiramate

Drug

This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.

carbamazepine

Drug

This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.

Valproic acid

Drug

This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.

Normal control

Drug

This is an observational study. Healthy female participants will be observed in Normal control group.

Primary outcomes

  1. Absolute Concentration of Calcium in Serum and Random Urine

    Time frame: 24 hours

    Bone and mineral metabolic marker represents the structure, cyclical metabolism, and hormone regulation of bone. Urinary calcium is one of the indicators of bone resorption (bone loss due to osteoclastic activity). Absolute concentration of calcium in serum and random urine will be assessed.

  2. Absolute Concentration of 25-hydroxy Vitamin D, Osteocalcin, Carboxy-terminal Telopeptide of type 1 collagen (CTx) and Somatomedin-C (IGF-1) in Serum

    Time frame: 24 hours

    Osteocalcin is a vitamin K-dependent calcium-binding protein synthesized by osteoblasts and found primarily in bones. Serum osteocalcin measurements provide a noninvasive specific marker of bone metabolism. CTx is marker for bone resorption (bone loss due to osteoclastic activity). IGF-1 has growth-regulating, insulin-like, and mitogenic activities. Absolute concentration of 25-hydroxy vitamin D, osteocalcin, carboxy-terminal telopeptide of type 1 collagen (CTx) and somatomedin-C (IGF-1) in serum will be assessed.

  3. Absolute Concentration of 1-alpha 25-dihydroxyvitamin D-3, Parathyroid Hormone (PTH) in Serum

    Time frame: 24 hours

    Bone and mineral metabolic marker represents the structure, cyclical metabolism, and hormone regulation of bone. 1-alpha 25-dihydroxyvitamin D-3 (vitamin D-3) and Parathyroid hormone (PTH) were assessed. The PTH maintains intracellular calcium levels in the body.

  4. Absolute Concentration of Bone-specific Alkaline Phosphatase (BSAP) in Serum

    Time frame: 24 hours

    Bone and mineral metabolic marker represents the structure, cyclical metabolism, and hormone regulation of bone. Bone-specific alkaline phosphatase (BSAP) reflects formation of organic matrix in bone. Absolute concentration of BSAP in Serum will be assessed.

  5. Absolute Concentration of Bicarbonate in Serum

    Time frame: 24 hours

    Bicarbonate levels in the blood are an index of the alkali reserve or buffering capacity. Difference in Bicarbonate level between topiramate, carbamazepine and valproic acid monotherapy groups will be assessed.

  6. Absolute Concentration of Calcium in Urine in 24 Hours

    Time frame: 24 hours

    Absolute concentration of calcium in urine will be examined by urine test.

Secondary outcomes

  1. Spine, Total hip and Femoral Neck Z-Score

    Time frame: 24 hours

    Z-score is number of standard deviations a participant's bone mineral density (BMD) differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are "best values" and negative values are "worst values". Z-score will be evaluated for spine, hip and femoral neck.

  2. Percentage of Participants With Osteopenia and Osteoporosis Based on Spine T-score

    Time frame: 24 hours

    Osteoporosis means reduction of bone mass without alteration in the composition of bone, leading to fractures. Osteopenia is a metabolic bone disease. The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD. Percentage of participants with osteopenia and osteoporosis based on spine T-score will be assessed.

  3. Percentage of Participants With Osteopenia and Osteoporosis Based on Spine Z-score

    Time frame: 24 hours

    Osteoporosis means reduction of bone mass without alteration in the composition of bone, leading to fractures. Osteopenia is a metabolic bone disease. The Z-score is number of standard deviations a participant's bone mineral density (BMD) differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are "best values" and negative values are "worst values". Z-score will be evaluated for spine, hip and femoral neck. Percentage of participants with osteopenia and osteoporosis based on spine Z-score will be assessed.

  4. Absolute Concentration of Phosphorus and Creatinine in Random Urine

    Time frame: 24 hours

    Absolute concentration of phosphorus and creatinine in urine will be examined by urine test.

  5. Absolute concentration of Sodium in Random Urine

    Time frame: 24 hours

    Absolute concentration of sodium in urine will be examined by urine test.

  6. Absolute Concentration of Phosphorus and Creatinine in 24 Hour Urine

    Time frame: 24 hours

    Absolute concentration of phosphorus and creatinine in 24 hour urine will be examined by urine test.

  7. Absolute concentration of Sodium in 24 Hour Urine

    Time frame: 24 hours

    Absolute concentration of sodium in 24 hour urine will be examined by urine test.

Sponsors and collaborators

Lead sponsor

Janssen Korea, Ltd., Korea

Industry

Registry information

Official study title

A Cross-sectional, Comparative, Multi-center Study to Investigate the Effect of Topiramate Monotherapy on Markers of Bone Mineral Metabolism and Bone Mineral Density in Premenopausal Women With Epilepsy

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Dec 11, 2009
Registry last updated
Jun 26, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.